drugset / Trial / NCT01831960

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

NCT01831960

Phase 2 Completed 42 enrolled Intrepid Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.

Timeline

Start
2013-04
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Clascoterone Small molecule 1 % Topical

Indications